Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma and pancreatic adenocarcinoma. In the current study, we utilized a DNA vaccine encoding human mesothelin (pcDNA3-Hmeso) to treat C57BL/6 mice challenged with luciferase-expressing, Hmeso-expressing ovarian cancer cell line, Defb29 Vegf-luc/ Hmeso. The therapeutic effect of the tumor-challenged mice was followed by noninvasive bioluminescence imaging systems. The mechanism of the antitumor effect was characterized by depletion of subsets of lymphocytes as well as adopted transfer of serum from pcDNA3-Hmesovaccinated mice. We found that vaccination with pcDNA3-Hmeso DNA vaccine generates a significant antitumor effect and promotes survival in mice challenged with Defb29 Vegfluc/Hmeso. Furthermore, we found CD4 + and CD8 + T-cell immune responses as well as the humoral immune responses are important for the observed antitumor effects in vaccinated mice. Our data indicated that vaccination with DNA vaccine targeting Hmeso could generate potent antitumor effects against mesothelin-expressing tumors through both T cell-mediated immunity as well as antibodymediated immunity.
Introduction
Intraperitoneal tumors such as ovarian cancer, malignant mesothelioma and pancreatic cancer represent serious diseases in humans. Ovarian cancer is the sixth most common malignancy in women and the leading cause of death from all gynecological cancers in the United States. 1 Malignant mesothelioma is rarely noticed at its early stages and therefore little is known of the establishment and progression of the disease (for review, see references Zellos and Sugarbaker 2 and Nowak et al.
3
). Pancreatic carcinoma is the fourth leading cause of cancer-associated deaths in the United States. 4 Current therapies such as surgery, chemotherapy and radiotherapy usually fail to control advanced stages of these diseases. Therefore, alternative approaches such as immunotherapy may serve as an important method to control these intraperitoneal tumors.
Antigen-specific immunotherapy is an attractive approach for the treatment of cancers since it has the potency to specifically eradicate systemic tumors and control metastases without damaging normal cells. The immune system has multiple collaborative effector mechanisms capable of killing target cells through two major response pathways: T cell-mediated immunity and the humoral response. T cells can generate tumor-specific immune responses by recognizing tumor-specific antigens (as peptide fragments) via a vast array of clonally distributed antigen receptors. Thus, identification of tumor-associated antigens expressed uniquely in intraperitoneal tumors is important for the development of antigen-specific cancer immunotherapy. B cells can also elicit a tumor-specific humoral response when activated by helper T cells to produce immunoglobulin G (IgG) antibodies specific to antigens. The antibodies will then respond by neutralization, opsonization or complement activation.
DNA vaccines have emerged as a potent antigenspecific immunotherapy since they have the ability to activate both T cell-mediated responses and humoral responses. Furthermore, DNA vaccines are a favorable form of vaccine for the control of infectious diseases and cancers since they offer many advantages over conventional vaccines, such as peptide or attenuated live pathogens (for review, see references [5] [6] [7] [8] ). For instance, DNA vaccines can be administered time after time without adverse effects and are relatively safe. In addition, DNA vaccines are comparatively easy to produce on a large scale and are able to yield products with high purity and stability. Most importantly, effective DNA vaccine delivery systems, such as direct intradermal administration of DNA vaccines via gene gun to professional antigen-presenting cells (APCs), have been well established. Using this delivery method, we have previously developed several innovative strategies to enhance DNA vaccine potency by modifying the properties of DNA-transfected APCs (for reviews, see references Hung and Wu 9 and Boyd et al.
10
). DNA vaccines targeting mesothelin as a tumor antigen may serve as an important form of vaccine against mesothelin-expressing intraperitoneal tumors, such as ovarian cancer, mesothelioma and pancreatic adenocarcinoma. Mesothelin has been found to be highly overexpressed in these intraperitoneal tumors. [11] [12] [13] [14] [15] Furthermore, it is absent or present in low levels in normal tissues and other types of cancer. 11 In addition, it has been suggested that mesothelin is a highly immunogenic protein in cancers with high mesothelin expression. For example, Ho et al. 16 showed that a high percentage of antimesothelin antibodies was found in ovarian cancer and mesothelioma patient sera and was associated with high expression of the antigen in tumors. In comparison, antibodies to mesothelin were found in only 4% of pharynx and larynx squamous cell carcinoma patients in a study done by Suaraez-Alverez et al. 17 Therefore, mesothelin represents a potentially ideal target antigen for the development of cancer immunotherapy using DNA vaccines against mesothelin-expressing tumors.
In the current study, we have generated a murine ovarian cancer cell line, Defb29 Vegf-luc/Hmeso that expresses human mesothelin (Hmeso). We found that treatment of mice challenged with Defb29 Vegf-luc/ Hmeso tumor cells with mesothelin DNA vaccine inhibits tumor growth and promotes survival. We have shown that protective antitumor effect generated by the mesothelin DNA vaccine is dependent in part on CD8 + and CD4
+ lymphocytes. Furthermore, we found that serum obtained from mesothelin DNA-immunized mice can kill tumor cells in vitro through rabbit complement and binds to mesothelin-expressing cancer cells. We also found that serum from mesothelin DNA-immunized mice produces an antitumor effect and leads to long-term survival in both immunocompetent and immunocompromised mice using adoptive serum transfer experiments. Therefore, employment of DNA vaccine encoding Hmeso in addition to the anti-Hmeso antibody containing serum obtained from vaccinating mice with mesothelin DNA vaccine serves as a potent antigen-specific cancer immunotherapy.
Results
Murine ovarian cancer cells transfected with DNA encoding Hmeso led to expression of Hmeso
We generated a Hmeso-expressing ovarian cancer cell line by transducing Defb29 Vegf-luciferase (Defb29 Vegfluc) cells 18 with retrovirus encoding full-length Hmeso (Defb29 Vegf-luc/Hmeso). To characterize the Hmeso expression of the transduced cells, we performed flow cytometry analysis using Hmeso-specific mouse monoclonal antibody, CAK-1. As shown in Figure 1 , Defb29 Vegf-luc/Hmeso cells expressed Hmeso (left panel). In comparison, Defb29 Vegf-luc cells without transduction showed no expression of Hmeso (right panel). Thus, our data indicate that transduction of Defb29 Vegf-luc cells with retrovirus encoding Hmeso leads to expression of Hmeso.
Treatment with pcDNA3-Hmeso DNA vaccine inhibits tumor growth and promotes survival in mice challenged with Defb29 Vegf-luc/Hmeso tumor cells
To characterize the therapeutic effects of treatment with Hmeso DNA vaccine, we first challenged C57BL/6 mice with 5 Â 10 5 /mouse of Defb29 Vegf-luc/Hmeso cells. Three days later, tumor-challenged mice were treated with empty vector DNA (pcDNA3) or human-mesothelin DNA (pcDNA3-Hmeso) vaccines. Tumor growth in challenged mice was then monitored using bioluminescent imaging systems. As shown in Figure 2a , we observed a significant reduction in luciferase activity in Defb29 Vegf-luc/Hmeso tumor-bearing mice treated with pcDNA3-Hmeso compared to tumor-challenged mice treated with pcDNA3 (*P ¼ 0.585). A graphical representation of the luminescent activity data is depicted in Figure 2b . We also characterized the survival of the treated mice using the Kaplan-Meier survival analysis. As shown in Figure 2c , prolonged survival was observed in tumor-challenged mice treated with pcDNA3-Hmeso compared to mice treated with pcDNA3 (*Po0.001). Thus, our data indicate that treatment with pcDNA3-Hmeso DNA leads to significant antitumor effects and prolonged survival in mice bearing mesothelin-expressing Defb29 Vegf-luc/Hmeso tumors.
CD8
+ and CD4 + T lymphocytes are important for the protective antitumor effects generated by pcDNA3-Hmeso DNA vaccine
To determine the subset of lymphocytes that are important for the antitumor effect, we performed in vivo depletion experiments using monoclonal antibodies specific for CD4 + T cells, CD8 + T cells or natural killer (NK) cells. C57BL/6 mice were immunized with the pcDNA3-Hmeso DNA vaccine. One week after vaccination, depletion was initiated of pcDNA3-Hmeso-immunized groups. Depletion occurred every other day for 1 week and then once a week through follow-up imaging. Two weeks after the last vaccination, all mice were challenged with Defb29 Vegf-luc/Hmeso tumor cells. Another group of C57BL/6 mice were vaccinated with pcDNA3 as a tumor growth control. Tumor growth was Figure 1 Flow cytometry analysis to characterize the expression of human mesothelin (Hmeso) in Defb29 Vegf-luc/Hmeso cell line. Characterization of Hmeso expression was performed in Defb29 Vegf-luc/Hmeso and Defb29 Vegf-luc cells using flow cytometry analysis. The cell lines were stained with the Hmeso-specific mouse monoclonal antibody CAK-1, followed by flow cytometry analysis. Mouse IgG1 isotype was used as a control.
DNA vaccination controls human mesothelin tumors
C-L Chang et al monitored using bioluminescent imaging systems. As shown in Figure 3a , we observed a significant decrease in luciferase activity in pcDNA3-Hmeso-vaccinated mice compared to pcDNA3-vaccinated mice, indicating preventive antitumor effects of pcDNA3-Hmeso DNA vaccination (*P ¼ 0.05). In addition, a significant increase in luciferase activity was observed in pcDNA3-Hmesovaccinated mice depleted of CD8 + or CD4 + T cells compared to pcDNA3-Hmeso-vaccinated mice without depletion or with NK depletion. Furthermore, as shown in Figure 3b , prolonged survival was observed in 100% of the pcDNA3-Hmeso DNA-vaccinated mice without lymphocyte depletion and with NK depletion as compared to only 40% of the pcDNA3-Hmeso DNAvaccinated mice depleted of CD8 + and CD4 + cells. Our data suggest that immunization of mice with pcDNA3-Hmeso leads to significant protective antitumor effect and prolonged survival in mice challenged with Defb29 Vegf-luc/Hmeso tumor cells. Furthermore, our results suggest that, CD8 + T cells and CD4 + T cells but not NK cells contribute to the observed protective antitumor effects.
Immunization of mice with pcDNA3-Hmeso elicits strong Hmeso-specific antibody responses
To characterize the antibody response in mice immunized with pcDNA3-Hmeso DNA vaccine, we performed flow cytometry analyses of mesothelin-expressing and nonmesothelin-expressing cell lines using sera from vaccinated mice. Sera were collected from pcDNA3-Hmesoimmunized C57BL/6 mice 1 week after the last immunization and used to stain the various ovarian cancer cell lines: Defb29 Vegf-luc/Hmeso (murine), Defb29 Vegf-luc (murine) and OVCAR3 (human). Sera from naive C57BL/ 6 mice were used as a control. As shown in Figure 4 , Defb29 Vegf-luc/Hmeso and OVCAR3 cell lines, both known to express Hmeso, showed significant shifts of fluorescent signal. In comparison, no specific staining was observed in Defb29 Vegf-luc cells, which were used as a negative control. Furthermore, no specific staining was observed when staining mesothelin-expressing cell lines with sera collected from naive mice. These data suggest that immunization of C57BL/6 mice induces Hmesospecific antibody responses in vaccinated mice. 
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Hmeso-specific antibodies from pcDNA3-Hmesoimmunized mice cause complement-mediated lysis of Defb29 Vegf-luc/Hmeso cells in vitro
To determine whether the Hmeso-specific antibodies present in sera collected from pcDNA3-Hmeso-vaccinated mice can cause complement-mediated lysis of Hmeso-expressing tumor cells in vitro, we performed complement-dependent cytotoxicity experiments using Defb29 Vegf-luc/Hmeso or Defb Vegf-luc cell lines with rabbit sera for complement. As shown in Figure 5a , tumor cell lysis was observed specifically in Defb29 Vegfluc/Hmeso cells incubated with sera collected from pcDNA3-Hmeso-vaccinated mice and complement but not with sera collected from naive mice and complement, as indicated by reduced luciferase expression (Po0.02). No specific lysis was observed when Defb29 Vegf-luc cells were incubated with sera collected from pcDNA3-Hmeso-vaccinated mice and complement or with sera collected from naive mice with complement. The Anti-CD4 Anti-CD8 Anti-NK pcDNA3 vaccinated Figure 3 In vivo antibody depletion experiment. C57BL/6 mice (five per group) were intraperitoneally (i.p.) immunized with pcDNA3-Hmeso twice at a 1-week interval via gene gun. One week after the last vaccination, the pcDNA3-Hmeso-vaccinated mice were depleted of either CD8, CD4 or NK cells using relevant antibodies every other day for 1 week and then once every week, as described in the Materials and methods section. A group of nondepleted pcDNA3-Hmeso-vaccinated mice was used as a control. Two weeks after vaccination, depleted and nondepleted mice were challenged with 1 Â Adoptive transfer of Hmeso-specific antibodies leads to long-term survival of Defb29 Vegf-luc/Hmeso tumor-bearing immunocompetent mice
To characterize the antitumor effects generated by Hmeso-specific antibodies in serum from pcDNA3-Hmeso-immunized mice in the absence of T cells, we performed serum transfer experiments using Defb29 Vegf-luc/Hmeso tumor-bearing athymic nude mice. To characterize the influence of sera derived from pcDNA3-Hmeso-immunized mice on the survival of C57BL/6 mice challenged with Defb29 Vegf-luc/Hmeso cells, we performed serum transfer experiments using sera from immunized mice or naive mice. Since treatment with pcDNA3 showed no antitumor effect, serum from pcDNA3-immunized mice would not be significantly different from serum from naive mice. In fact, we have done the first experiment with naive mice challenged with Defb29 Vegf-luc/Hmeso cells and found no difference in luciferase expression from challenged mice treated with pcDNA3 (data not shown). Therefore, we have used serum from naive mice for the experiments involving treatment with serum. C57BL/6 mice with established Defb29 Vegf-luc/Hmeso tumors were intraperitoneally (i.p.) injected with sera collected from pcDNA3-Hmeso-immunized mice or naive mice. The survival of the tumor-challenged mice was characterized using Kaplan-Meier survival analysis. As shown in Figure 6 , tumor-challenged mice that received antiHmeso serum showed significantly better survival compared to the survival of challenged mice that received sera from naive mice (*P ¼ 0.03). Thus, these data indicate that Hmeso-specific antibodies in sera collected from pcDNA3-Hmeso-immunized mice are able to control Hmeso-expressing murine ovarian tumors in immunocompetent mice.
Adoptive transfer of Hmeso-specific antibodies leads to long-term survival of Defb29 Vegf-luc/Hmeso tumor-bearing immunocompromised mice
To characterize the antitumor effects generated by Hmeso-specific antibodies in sera from pcDNA3-Hmeso-immunized mice in the absence of T cells, we performed serum transfer experiments using Defb29 Vegf-luc/Hmeso tumor-bearing athymic nude mice. Recipient athymic nude mice were subcutaneously challenged with 5 Â 10 4 /mouse of Defb29 Vegf-luc/ Hmeso cells. Equal tumor growth among mice was confirmed by bioluminescence imaging. One week after tumor challenge, tumor-bearing mice were i.p. injected with serum from pcDNA3-Hmeso-immunized mice or naive mice. Tumor growth among challenged mice was characterized by bioluminescence imaging. As shown in Figure 7a , tumor-bearing mice treated with sera from pcDNA3-Hmeso-immunized mice show significantly lower tumor volume over time than mice treated with sera from naive mice, as indicated by lower luciferase activity (*P ¼ 0.013). A graphical representation of the tumor volume by quantification of luminescent activity is depicted in Figure 7b . We further characterized the survival of tumor-challenged mice following treatment with sera from pcDNA3-Hmeso-immunized mice using Kaplan-Meier survival analysis. As shown in Figure 7c , tumor-bearing mice that received sera from pcDNA3-Hmeso-immunized mice showed significantly better long-term survival compared to tumor-bearing mice that received sera from naive mice (*P ¼ 0.011). Thus, these data indicate that treatment with Hmeso-specific antibody containing sera is capable of controlling Hmeso-expressing murine ovarian tumors in the absence of T cells.
Adoptive transfer of Hmeso-specific antibodies leads to long-term survival of OVCAR3-luc/GFP tumor-bearing immunocompromised mice
To determine if Hmeso-specific antibodies in sera from pcDNA3-Hmeso-immunized mice are capable of controlling mesothelin-expressing human ovarian cancer, we performed serum transfer experiments using OVCAR3-luc/GFP tumor-bearing athymic nude mice. Recipient athymic nude mice were subcutaneously challenged with 5 Â 10 4 /mouse of OVCAR3-luc/GFP cells. Equal tumor growth among mice was confirmed by bioluminescence imaging. One week after tumor challenge, OVCAR3-luc/GFP tumor-bearing mice were i.p. injected with sera from pcDNA3-Hmeso-immunized mice or naive mice. As shown in Figure 8a , OVCAR3-luc/GFPchallenged mice treated with sera from pcDNA3-Hmesoimmunized mice show significantly lower tumor volume Figure 4 Flow cytometry analysis to characterize the expression of human mesothelin (Hmeso) in murine and human ovarian cancer cell lines. Hmeso-specific antibody containing serum was generated by immunization of C57BL/6 mice with pcDNA3-Hmeso DNA vaccine 3 times at 1-week intervals via gene gun. One week after vaccination, blood sera were collected from immunized mice and used to stain murine and human cancer cell lines. The characterization of Hmeso expression in Defb29 Vegf-luc/Hmeso, Defb29 Vegf-luc and OVCAR3 was performed with flow cytometry analysis using sera collected from pcDNA3-Hmeso-immunized mice. Sera from naive mice were used as a negative control.
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over time than tumor-bearing mice treated with serum from naive mice (*P ¼ 0.03). We further characterized the survival of tumor-challenged mice treated with sera from pcDNA3-Hmeso-immunized mice using Kaplan-Meier survival analysis. As shown in Figure 8b , tumor-challenged mice that received sera from pcDNA3-Hmeso-immunized mice showed better survival compared to challenged mice that received sera from naive mice, although the differences are not statistically significant (*P ¼ 0.059). Thus, these data indicate that treatment of OVCAR3-luc/GFP-challenged athymic nude mice with anti-Hmeso serum induces therapeutic antitumor effects and borderline prolonged survival compared to treatment of challenged mice with naive serum.
Discussion
In the current study, we created a murine ovarian cancer cell line that expressed Hmeso for our DNA vaccine studies. We found that the Defb29 Vegf-luc/Hmeso tumor-bearing mice can be effectively controlled by treatment with Hmeso DNA vaccine, pcDNA3-Hmeso. In addition, we found that both CD4 + and CD8 + T cells but not NK cells contribute to the antitumor effects generated by vaccination with pcDNA3-Hmeso DNA vaccine. Furthermore, we found that the Hmeso-specific antibodies in sera collected from pcDNA3-Hmeso DNAimmunized mice are capable of controlling Hmesoexpressing murine and human ovarian cancer cell lines, resulting in prolonged survival of tumor-bearing mice. Our results serve as an important foundation for future clinical translation. 
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While our system demonstrated significant therapeutic effects against Hmeso-expressing ovarian cancer with pcDNA3-Hmeso DNA vaccine, it does not address the issue of tolerance. Hmeso is not normally expressed in the mouse, thus no tolerance against Hmeso is expected in mice. In fact, we have also performed similar experiments using a DNA vaccine encoding murine mesothelin in C57BL/6 mice challenged with murine mesothelin-expressing mouse ovarian surface epithelial cancer (MOSEC) cells. Treatment of mice challenged with MOSEC tumor cells with the murine mesothelin DNA vaccine failed to control tumor growth (data not shown). Thus, to extend our study to future clinical translation, we need to consider innovative strategies that are capable of breaking tolerance against endogenous antigens. For example, the employment of xenogeneic antigens for the DNA vaccine development has been shown to effectively break tolerance in some cancer models. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Other strategies that are capable of breaking tolerance include the employment of suicidal DNA vectors and bacterial vectors. [29] [30] [31] [32] [33] Thus, the use of tolerance-breaking methods in conjunction with therapeutic strategies targeting Hmeso may overcome this problem.
In the current study we observed that Hmeso-specific antibodies in sera collected from mice immunized with pcDNA3-Hmeso have therapeutic effects against Hmesoexpressing murine and ovarian tumors. The therapeutic effects translate into a better survival in tumor-bearing mice. Although the mechanism for the antitumor effects mediated by Hmeso-specific antibodies remains unclear, our in vitro data suggest that complement-mediated lysis may contribute to the antitumor effect (see Figure 5) . The encouraging results from this preclinical study suggest that the further development of mesothelin-specific antibody-based immunotherapy may represent a potentially plausible approach for the control of intraperitoneal mesothelin-expressing tumors. Currently, there is one early phase of clinical trials using humanized monoclonal antibodies against Hmeso in patients with mesothelin-expressing pancreatic cancer (Dr Elizabeth Jaffe, personal communication) and ovarian cancers (Dr Deborah Armstrong, personal communication) at Johns Hopkins Hospital.
In summary, we have shown that DNA vaccine encoding Hmeso is capable of generating therapeutic antitumor effects against Hmeso-expressing tumors through both T cell-mediated and humoral-mediated immune responses. Further development of the DNA vaccine employing strategies that are capable of breaking tolerance to Hmeso may lead to eventual clinical translation.
Materials and methods

Mice
Female C57BL/6 and athymic nude mice were acquired from the National Cancer Institute. All animals were maintained under specific pathogen-free conditions, and all procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals. 
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Cell lines
A syngeneic mouse ovarian epithelial cancer cell line ID8 transfected with VEGF-A and b-defensin 29 (named Defb29 Vegf) was a generous gift from Dr Coukos.
34
Defb29 Vegf-luc were generated by transducing Defb29 Vegf cells with the retrovirus containing luciferase pLucithy1.1 and flow cytometry sorting following the protocol described previously. 18 For stable expression of Hmeso on this cell line, Defb29 Vegf-luc was further transduced with retrovirus containing full-length mesothelin cDNA and isolated as described previously. 35 Growth rate of Defb29 Vegf-luc/Hmeso cells was comparable to those of Defb29 Vegf-luc cells (data not shown). Luciferase-and GFP-expressing OVCAR3 (OVCAR3-luc/GFP) was generated by transduction with a lentivirus containing luciferase and GFP. Lentiviral vector pCDH1-luc-EF1-GFP was transfected into Phoenix packaging cell line using lipofectamine (Invitrogen, Carlsbad, CA, USA) and the virion-containing supernatant was collected 48 h after transfection. The supernatant was then filtered through a 0.45 mm cellulose acetate syringe filter (Nalgene, Rochester, NY, USA) and used to infect OVCAR3 cells in the presence of 8 mg/ml Polybrene (Sigma-Aldrich, St Louis, MO, USA). Transduced cells were isolated using preparative flow cytometry with GFP signal.
Plasmid DNA constructs and DNA preparation
The generation of pcDNA3-Hmeso has been described previously. 35 A lentiviral construct pCDH-Luc-EF1-GFP (System Biosciences, Mountain View, CA, USA) expressing both luciferase and GFP was made to transduce the OVCAR3 cells. Firefly luciferase was amplified by PCR from pGL3-basic (Promega, Madison, WI, USA) and cloned into pCDF1-MCS2-EF1-copGFP (System Biosciences). All the constructs were verified by restriction analysis and DNA sequencing using ABI 3730 DNA Analyzer at Johns Hopkins DNA analysis facility.
Tumor treatment
Naive C57BL/6 (five per group) mice were i.p. injected with 5 Â 10 5 Defb29 Vegf-luc/Hmeso cells. After 3 days, mice were treated with 2 mg/mouse of pcDNA3-Hmeso or empty vector (pcDNA/myc-His) DNA vaccine through gene gun 3 times at 1-week interval. Tumor load in DNA-treated mice was evaluated by luminescence activity once per week for 8 weeks using IVIS Imaging System Series 200 (Xenogen, Cranbury, NJ, USA).
Tumor protection and depletion of lymphocyte subsets in vivo C57BL/6 mice (five per group) were vaccinated with 2 mg/mouse of empty vector (group 1) or pcDNA3-Hmeso DNA (groups 2-5) by gene gun 2 times at 1-week interval. Of them, mice groups 3-5 vaccinated with pcDNA3-Hmeso were i.p. injected with blocking antibody using a protocol similar to one described previously. 36 Mice were injected with 100 mg/mouse of purified rat monoclonal antibody GK1.5 (anti-CD4, group 3), mAb 2.43 (anti-CD8, group 4) or mAb PK136 (anti-NK1.1, group 5). Depletion was started 1 week after mesothelin DNA vaccination and continued every other day for 1 week and every week onwards. All the five groups of mice were then challenged i.p. with 1 Â 10 6 / mouse of Defb29 Vegf-luc/Hmeso cells 2 weeks after the last vaccination. Depletion was maintained by continuing the antibody injections weekly for the duration of the tumor-imaging follow-up. Differences in the luminescence activity of tumor growth were monitored once a week.
Antibody binding and flow cytometry analysis
Blood was obtained from C57BL/6 mice (five per group) vaccinated with 2 mg/mouse of pcDNA-Hmeso DNA vaccine 3 times at 1-week interval 1 week after the last vaccination. The presence of Hmeso-specific antibodies was characterized by staining the Defb29 Vegf-luc, Defb29 Vegf-luc/Hmeso and human OVCAR3 ovarian cancer cells using serum from pcDNA3-Hmeso DNAvaccinated mice in a 1:200 dilution, followed by Phycoerythrin-conjugated antimouse IgG antibody (eBioscience, San Diego, CA, USA) staining. Serum from naive mice was used as control. Analysis of cell staining was performed on a Becton-Dickinson FACScan with CELLQuest software (Becton Dickinson Immunocytometry System, Mountain View, CA, USA). 
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Adoptive serum transfer experiment in C57BL/6 and athymic nude mice Serum containing Hmeso-specific antibodies was prepared from C57BL/6 mice that were immunized with 2 mg/mouse pcDNA-Hmeso 3 times in 1-week interval. One week after last vaccination, sera obtained from these immunized mice or naive mice (control) were collected for adoptive therapy. C57BL/6 mice were challenged with 5 Â 10 5 /mouse of Defb29 Vegf-luc/Hmeso cells, and followed by IVIS bioluminescent imaging on day 3 to confirm equal amount of growing tumor in each mouse. Tumor-challenged mice (five per group) were subjected to adopted therapy with i.p. injection of serum from mesothelin-immunized mice or naive mice (100 ml/ mouse every 3 days for 4 times). Athymic nude mice were injected with 2 Â 10 5 /per mouse of Defb29 Vegfluc/Hmeso cells or OVCAR3-luc/GFP cells. Treatments with serum from immunized or naive mice were commenced after confirmation of equal amount of tumor growth on day 5 (for mice challenged with Defb29 Vegfluc/Hmeso tumor cells) and day 3 (for mice challenged with OVCAR3-luc/GFP tumor cells). These mice were followed for their tumor growth by IVIS bioluminescent imaging every week and also for their survival.
Complement-dependent toxicity assay
Target cells Defb29 Vegf-luc/Hmeso were seeded in 96-well plate (1 Â 10 4 /well). Sera collected from mice immunized with Hmeso (pcDNA-Hmeso) or nonimmunized mice were added into the well in the following amounts: 10, 1 and 0 ml and followed by a naive rabbit serum in a final dilution of 1:5, used for complement (Sigma-Aldrich) with culture medium in total volume of 100 ml.
37 Defb29 Vegf-luc cells were used as a negative control. After incubation for 6 h, cell viability was measured as bioluminescent activity by IVIS Imaging System Series 200.
Statistical analysis
All data expressed as means7standard deviation are representative of at least two different experiments. Comparisons between individual data points were made using a Student's t-test. Differences in survival between experimental groups were analyzed using the KaplanMeier approach. The statistical significance of group differences will be assessed using the log-rank test.
